Pulmonary Fibrosis News Home | Pulmonary Fibrosis News
Oct 17, 2024 · Researchers will team up to develop pulmonary fibrosis stem cell models. The Center for Regenerative Medicine (CReM) of Boston University and Boston Medical Center will collaborate with GSK to develop stem cell-based models to better understand pulmonary fibrosis and identify new targets for treatments that may halt or slow its progression ...
New prototype therapy may repair IPF lung scarring by …
by Steve Bryson, PhD April 26, 2024. Researchers have developed an inhalable prototype medicine that may be able to repair lung scarring caused by idiopathic pulmonary fibrosis (IPF) by stimulating the growth of stem cells directly in the lungs, a study reports. The study provides pharmacological proof of concept for an upcoming Phase 1 ...
Potential pulmonary fibrosis treatment CAL101 does well in Phase …
2 days ago · by Marisa Wexler, MS November 8, 2024. CAL101, an investigational therapy with the potential to treat pulmonary fibrosis, showed a favorable safety and pharmacological profile in a Phase 1 clinical trial, according to results announced by Calluna Pharma, its developer. “These results are an important step forward in the development of our ...
BMS-986278 declared breakthrough therapy for progressive PF
Oct 27, 2023 · The FDA’s decision to grant breakthrough therapy designation to BMS-986278 was based on results from a global Phase 2 clinical trial (NCT04308681) assessing the safety and efficacy of BMS-986278 in 278 people with idiopathic PF (IPF) and progressive PF. Patients were assigned randomly to receive either 30 or 60 mg of the therapy, or a placebo ...
Primary goal met for IPF in Phase 3 clinical trial of nerandomilast
Sep 27, 2024 · A Phase 3 clinical trial testing Boehringer Ingelheim ’s oral investigational treatment nerandomilast in people with idiopathic pulmonary fibrosis (IPF) has met its primary goal of demonstrating the therapy outperformed a placebo at improving lung function or preventing its decline after a year, recently announced top-line data shows.
Pulmonary Fibrosis Symptoms, Diagnosis, Prognosis and Treatment
Recent Posts. Now you know: Updates from my journey living with IPF November 5, 2024; My increasing interest in my family medical history October 29, 2024; Researchers will team up to develop pulmonary fibrosis stem cell models October 25, 2024; Keeping track of meds is part of my post-transplant plan October 22, 2024; Pro-fibrotic immune cell detected in lungs of long COVID-19 patients ...
Esbriet, Ofev Benefit IPF Patients in Clinical Practice, Data Show
Apr 6, 2021 · Esbriet, Ofev Found to Benefit IPF Patients in Clinical Practice. Two approved anti-fibrotics are proving to be safe and effective in treating idiopathic pulmonary fibrosis (IPF), a study with real-world data reports. The data showed Esbriet (pirfenidone) and Ofev (nintedanib) increased progression-free survival, slowed down lung function ...
Study: ENV-101 improves IPF lung function, reverses fibrosis
by Andrea Lobo June 7, 2024. Endeavor BioMedicines ’ ENV-101 improved lung function and reversed key signs of lung scarring in people with idiopathic pulmonary fibrosis (IPF), according to data from a completed Phase 2a trial. The results, which also showed the treatment had an acceptable tolerability profile, were presented in a late ...
First Patient Enrolled in Phase 3 Trial Testing BI 1015550
Oct 28, 2022 · by Steve Bryson, PhD October 28, 2022. Boehringer Ingelheim has enrolled the first patient in FIBRONEER-IPF, a Phase 3 clinical trial evaluating the efficacy, safety, and tolerability of BI 1015550, an investigational therapy for people with idiopathic pulmonary fibrosis (IPF). The trial is part of the FIBRONEER global program, which also ...
IPF Patients Live Longer on Ofev Compared with Placebo, Analysis …
Apr 16, 2019 · The analysis included data collected from a total of 1,126 IPF patients (mean age of 66.9 years), who were treated twice daily with 150 mg of Ofev, and 565 patients treated with a placebo. Participants received the treatment for a mean period of 27.7 months, with some patients receiving the treatment for a maximum of 93.1 months.